{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T01:29:16Z","timestamp":1769909356093,"version":"3.49.0"},"reference-count":146,"publisher":"Baishideng Publishing Group Inc.","issue":"38","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJG"],"published-print":{"date-parts":[[2015]]},"DOI":"10.3748\/wjg.v21.i38.10760","type":"journal-article","created":{"date-parts":[[2015,10,14]],"date-time":"2015-10-14T09:56:02Z","timestamp":1444816562000},"page":"10760","source":"Crossref","is-referenced-by-count":26,"title":["Impact of new treatment options for hepatitis C virus infection in liver transplantation"],"prefix":"10.3748","volume":"21","author":[{"given":"Elda","family":"Righi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003258669"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2008.01934.x"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2000.9714"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.05.013"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1997.v112.pm9024300"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510310236"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/BF02893380"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/lt.23551"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.lts.2003.09.018"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2012.09.010"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/tp.0000000000000629"},{"key":"ref12","unstructured":"AASLD and IDSA Guidelines. Recommendations for Testing, Managing, and Treating Hepatitis C. When and in whom to initiate HCV Therapy. Accessed April 2, 2015. Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/www.hcvguidelines.org\/\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/www.hcvguidelines.org\/<\/ext-link>."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12074"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.03.004"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24370"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.03.025"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-5-200403020-00010"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1021\/jm060325b"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2174\/187152606776056706"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010494"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009482"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012912"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014463"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24641"},{"key":"ref27","unstructured":"Vertex Pharmaceuticals discontinues Incivek. Canadian Treatment Action Council website. Accessed February 19, 2015. Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ctac.ca\/multimedia-press\/treatmentaccessnews\/vertex-pharmaceuticals-discontinues-incivek\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/www.ctac.ca\/multimedia-press\/treatmentaccessnews\/vertex-pharmaceuticals-discontinues-incivek<\/ext-link>."},{"key":"ref28","unstructured":"Clinical Pharmacology [database online]. Accessed March 12, 2015. 2014; Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicalpharmacology-ip.com\/default.aspx\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/clinicalpharmacology-ip.com\/default.aspx<\/ext-link>."},{"key":"ref29","unstructured":"FDA approves Sovaldi for chronic hepatitis C. FDA news release US food and Drug administration. Accessed December 6, 2013. Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/www.Fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm377888.htm\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/www.Fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm377888.htm<\/ext-link>."},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00054-12"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1021\/jm100863x"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214853"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214854"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2014.09.026"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)61142-8"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61036-9"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316366"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402355"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402869"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.04.045"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1401561"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27567"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)70050-2"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Reddy KR, Bourli&egrave;re M, Sulkowski M, Omata M, Zeuzem S, Feld JJ, Lawitz E, Marcellin P, Welzel TM, Hyland R. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. Hepatology 2015;62:79-86.","DOI":"10.1002\/hep.27826"},{"key":"ref45","unstructured":"Bourliere M, Sulkowski MS, Omata M, Zeuzem S, Feld LL, Lawitz E, Marcellin P, Hyland RH, Ding X, Yang JC, Knox SJ, Pang PS, Subramanian M, Symonds WT, McHutchison JG, Mangia A, Gane EJ, Reddy KR, Mizokami M, Pol S, Afdhal NH. An Integrated Safety and Efficacy Analysis of &gt;500 Patients with Compensated Cirrhosis Treated with Ledipasvir\/Sofosbuvir with or without Ribavirin. 65th Annual Meeting of the American Association for the Study of Liver diseases, November 7-11, 2014; Boston, United States. ."},{"key":"ref46","unstructured":"Dieterich D, Bacon BR, Flamm SL, Kowdley KV, Milligan S, Tsai N, Yonoussi Z, Lawitz E. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population. 65th Annual Meeting of the American Association for the Study of Liver diseases, November 7-11, 2014; Boston, United States. ."},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61795-5"},{"key":"ref48","unstructured":"ClinicalTrials.gov. Safety and Efficacy of Grazoprevir (MK-5172) Elbasvir (MK-8742) in Participants with Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052) (C-SURFER). Identifier: NCT02092350. ."},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.3868"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2003.50268"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2002.35856"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2002.30141"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3880043"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.31773"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70352-5"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3062.2000.020403.x"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1002\/lt.21646"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Crespo G, Mari\u00f1o Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology 2012;142:1373-1383.e1.","DOI":"10.1053\/j.gastro.2012.02.011"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199506013322202"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115723"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2004.11.046"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02642.x"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1002\/lt.21613"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1002\/lt.21524"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.32418"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24074"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1002\/lt.21784"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1002\/lt.21954"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199805150-00006"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510280333"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23340"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21440"},{"key":"ref73","unstructured":"Van Thiel DH, Faruki H, Friedlander L, Fagiuoli S, Caraceni P, Molloy PJ, Kania RJ, Wright HI. Combination treatment of advanced HCV associated liver disease with interferon and G-CSF. Hepatogastroenterology 1995;42:907-912."},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20793"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2002.31748"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2003.50166"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.03.041"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.11.015"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25976"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.109309"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Curry MP, Forns X, Chung RT, Terrault NA, Brown R, Fenkel JM, Gordon F, O&rsquo;Leary J, Kuo A, Schiano T. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2015;148:100-107.e1.","DOI":"10.1053\/j.gastro.2014.09.023"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.05.010"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.7326\/M14-1211"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27814"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, McPhee F, Hughes E, Noviello S, Swenson ES. Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirhhosis or posttransplant recurrence: phase 3 ALLY-1 study. 50th International Liver Congress. April 22-26 2015; Vienna, Austria. .","DOI":"10.1016\/S0168-8278(15)30154-9"},{"key":"ref86","unstructured":"AASLD and IDSA Guidelines. Recommendations for Testing, Managing, and Treating Hepatitis C. Unique patient populations: patients with decompensated cirrhosis. Accessed June 30, 2015. Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/www.hcvguidelines.org\/\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/www.hcvguidelines.org\/<\/ext-link>."},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2014.10.002"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2003.50255"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1002\/lt.20572"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2009.01023.x"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2004.00648.x"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2007.02126.x"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1002\/lt.21312"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2005.08.009"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1002\/lt.20883"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2005.10.060"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01470.x"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.02.015"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000100481.14514.BB"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2003.12.015"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2003.10.083"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01362.x"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408921"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080528"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)60215-3"},{"key":"ref106","unstructured":"Burton JR, Everson GT. Initial experience with telaprevir for treating hepatitis C virus in liver recipients: virologic response, safety, and tolerability. Am J Transplant 2012;12 Suppl 3:188."},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.08.018"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1002\/lt.23669"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12616"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.10.001"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27681"},{"key":"ref112","unstructured":"AASLD and IDSA Guidelines. Recommendations for Testing, Managing, and Treating Hepatitis C. Summary of Recommendations for Patients Who Develop Recurrent HCV Infection Post-Liver Transplantation. Accessed April 3, 2015. Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/www.hcvguidelines.org\/\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/www.hcvguidelines.org\/<\/ext-link>."},{"key":"ref113","unstructured":"Reddy KR, Everson GT, Flamm SL, Denning JM, Arterburn S, Brandt-Sarif T, Pang PS, Dvory-Sobol H, McHutchison GH, Curry MP, Charlton M. Ledipasvir\/Sofosbuvir With Ribavirin for the Treatment of HCV in Patients With Post-Transplant Recurrence: Preliminary Results of a Prospective, Multicenter Study. 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 7-11, 2014; Boston, United States. ."},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.07.063"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2014.06.004"},{"key":"ref116","unstructured":"Fontana R. High efficacy and favorable safety profile of Daclatasvir based all oral antiviral therapy in liver Transplant recipients with severe recurrent HCV. 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 7-11, 2014; Boston, United States. ."},{"key":"ref117","unstructured":"Mantry P, Kwo PY, Coakley E, Te HS, Vargas HE, Brown RS, Gordon FD, Levitsky J, Terrault N, Burton JR. High Sustained Virologic Response Rates in Liver Transplant Recipients With Recurrent HCV Genotype 1 Infection Receiving ABT-450\/r\/Ombitasvir Dasabuvir Plus Ribavirin. 65th Annual Meeting of the American Association for the Study of Liver diseases, November 7-11, 2014, Boston, United States. ."},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1002\/lt.24126"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27770"},{"key":"ref120","unstructured":"Brown RS, Reddy KRJ, O&rsquo;Leary JG, Kuo A, Morelli G, Stravitz RT. Safety and efficacy of new DAA-based therapy for hepatitis C post-transplant: interval results from the HCV-TARGET longitudinal, observational study. Hepatology 2014;60:1269A."},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.15.1632"},{"key":"ref122","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.09.010"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.1002\/lt.22431"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.74"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.1002\/lt.20233"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12339"},{"key":"ref127","doi-asserted-by":"publisher","DOI":"10.1086\/426021"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-008-7319-5"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.07.034"},{"key":"ref130","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i18.5353"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21990"},{"key":"ref132","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000516"},{"key":"ref133","unstructured":"Moreno A, Perez-Elias MJ, Barcena R, Quereda C, Casado JL, Dronda F, Mateos ML, Diaz A, Moreno S. ."},{"key":"ref134","unstructured":"Rockstroh JK, Puoti M, Rodriguez-Torres M, Dieterich D, Gaggar A, Ni L, Massetto B, Svarovskaia ES, Brainard DM, Subramanian M. Sofosbuvir and Ribavirin therapy for the Treatment of HIV\/HCV coinfected patients with HCV GT1-4 Infection: The PHOTON-1 and -2 Trials. Presented at: 65th Annual Meeting of the American Association for the Study of Liver diseases, November 7-11, 2014, Boston, United States. ."},{"key":"ref135","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.1373"},{"key":"ref136","unstructured":"Naggie S, Cooper C, Saag M, Yang J. Ledipasvir\/sofosbuvir for 12 wk in patients coinfected with HCV and HIV-1 Presented at: 22nd Conference on Retroviruses and Opportunistic Infections (CROI) 2015. February 23-26; 2015;Seattle, United States."},{"key":"ref137","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.1328"},{"key":"ref138","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61793-1"},{"key":"ref139","unstructured":"Del Bello DP, Bichoupan K, Yalamanchili R. Real-world data on HIV positive patients with HCV genotype 1,2 and 3 on sofosbuvir- and simeprevir containing regimens. Presented at: 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). November 7-1, 2014, Boston, United States. ."},{"key":"ref140","unstructured":"Wyles D, Ruane P, Sulkowski, Dieterich D. Daclatasvir in combination with sofosbuvir for HIV\/HCV coinfection: ALLY-2 study. 22nd Conference on Retroviruses and Opportunistic Infections (CROI), February 23-26, 2015; Seattle, United States. ."},{"key":"ref141","doi-asserted-by":"publisher","DOI":"10.1177\/1060028015576180"},{"key":"ref142","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.10.032"},{"key":"ref143","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214854"},{"key":"ref144","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316145"},{"key":"ref145","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(03)00310-6"},{"key":"ref146","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181d2bfca"}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v21\/i38\/10760.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T14:52:51Z","timestamp":1567263171000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v21\/i38\/10760.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":146,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.3748\/wjg.v21.i38.10760","relation":{},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]}}}